STIM - Neuronetics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.38
+0.38 (+3.17%)
As of 10:44AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.00
Open12.02
Bid12.22 x 2200
Ask12.44 x 1000
Day's Range11.78 - 12.48
52 Week Range3.60 - 39.39
Volume78,532
Avg. Volume95,510
Market Cap226.642M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.95
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.50
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Neuronetics to Present at the JMP Life Sciences Conference

    MALVERN, Pa., June 05, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire17 days ago

    NeuroStar® Advanced Therapy Receives National Reimbursement Listing in Japan

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) listed reimbursement for the Company’s NeuroStar® Advanced Therapy System for the treatment of Major Depressive Disorder (MDD) in adults. MHLW and Japan's Central Social Insurance Medical Council (Chuikyo) approved reimbursement earlier this year and the listing is effective as of June 1, 2019.

  • Business Wire22 days ago

    INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Neuronetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neuronetics, Inc. (“Neuronetics” or “the Company”) (NASDAQ: STIM) for violations of state laws. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

  • Business Wire23 days ago

    Glancy Prongay & Murray LLP Announces Investigation on Behalf of Neuronetics, Inc. Investors (STIM)

    Glancy Prongay & Murray LLP Announces its investigation on behalf of Neuronetics, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.

  • GlobeNewswire28 days ago

    Neuronetics to Present at the William Blair 39th Annual Growth Stock Conference

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Chris Thatcher, President and Chief Executive Officer, will participate in the William Blair 39th Annual Growth Stock Conference on Wednesday, June 5, 2019, at the Loews Chicago Hotel in Chicago, Illinois. The Company is scheduled to present at the conference at 10 a.m. CT (11 a.m. ET) the same day.

  • GuruFocus.comlast month

    General Electric Co Buys Westinghouse Air Brake Technologies Corp, Neuronetics Inc

    Fairfield, CT, based Investment company General Electric Co buys Westinghouse Air Brake Technologies Corp, Neuronetics Inc during the 3-months ended 2019Q1, according to the most recent filings of the ...

  • NeuroStar® Advanced Therapy Survey Finds Majority of Americans Don't Feel Very Equipped to Discuss Depression With Loved Ones
    PR Newswirelast month

    NeuroStar® Advanced Therapy Survey Finds Majority of Americans Don't Feel Very Equipped to Discuss Depression With Loved Ones

    MALVERN, Pa., May 14, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM) — NeuroStar® Advanced Therapy, the established leader in transcranial magnetic stimulation (TMS) — a non-drug, non-invasive depression treatment — today announced results from its national survey, conducted in honor of Mental Health Awareness Month, that uncover insights on awareness, knowledge and perception of depression in America. The survey was conducted online within the United States by The Harris Poll on behalf of NeuroStar Advanced Therapy among 2,010 U.S. adults.

  • Neuronetics, Inc. (STIM) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Neuronetics, Inc. (STIM) Q1 2019 Earnings Call Transcript

    STIM earnings call for the period ending March 31, 2019.

  • Associated Presslast month

    Neuronetics: 1Q Earnings Snapshot

    On a per-share basis, the Malvern, Pennsylvania-based company said it had a loss of 42 cents. The medical device company focused on psychiatric disorders posted revenue of $12.7 million in the period. ...

  • GlobeNewswirelast month

    Neuronetics Reports First Quarter 2019 Financial and Operating Results

    MALVERN, Pa., May 07, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • Is Neuronetics, Inc. (NASDAQ:STIM) A Financially Sound Company?
    Simply Wall St.2 months ago

    Is Neuronetics, Inc. (NASDAQ:STIM) A Financially Sound Company?

    While small-cap stocks, such as Neuronetics, Inc. (NASDAQ:STIM) with its market cap of US$282m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a dow...

  • GlobeNewswire2 months ago

    Neuronetics to Report First Quarter 2019 Financial and Operating Results and Host Conference Call

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release first quarter 2019 financial and operating results, and certain guidance for the second quarter and full year 2019, prior to market open on Tuesday, May 7, 2019. Chris Thatcher, Chief Executive Officer, and Peter Donato, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 a.m. Eastern Time the same day. To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 3888389, approximately ten minutes prior to start time.

  • GlobeNewswire3 months ago

    NeuroStar® Advanced Therapy to Receive Reimbursement Approval in Japan

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, announced today that Japan's Central Social Insurance Medical Council (Chuikyo) has approved the recommendation by Japan’s Ministry of Health, Labour and Welfare (MHLW) expert review panel to provide reimbursement for NeuroStar Advanced Therapy for the treatment of Major Depressive Disorder (MDD) in adults. The reimbursement is expected to go into effect on or about June 1, 2019.

  • GlobeNewswire3 months ago

    Neuronetics to Present at the 18th Annual Needham & Company Healthcare Conference

    MALVERN, Pa., March 26, 2019 -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • PR Newswire3 months ago

    Neuronetics, Inc. Celebrates Dr. Charles Epstein's Contributions to Magnetic Stimulation Research

    MALVERN, Pa., March 21, 2019 /PRNewswire/ -- Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, applauds Dr. Charles M. Epstein, the neurologist who introduced magnetic stimulation at Emory University, for receiving the Start-Up of the Year Award at the 13th Annual Celebration of Technology and Innovation. The annual program is hosted by Emory University's Office of Technology Transfer and recognizes faculty entrepreneurs and their innovative discoveries.

  • Neuronetics, Inc. (STIM) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Neuronetics, Inc. (STIM) Q4 2018 Earnings Conference Call Transcript

    STIM earnings call for the period ending December 31, 2018.

  • GlobeNewswire4 months ago

    Neuronetics Reports Fourth Quarter and Full Year 2018 Financial and Operating Results

    MALVERN, Pa., March 05, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • ACCESSWIRE4 months ago

    Neuronetics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 5, 2019 / Neuronetics, Inc. (NASDAQ: STIM ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 5, 2019 at 8:30 AM Eastern ...

  • PR Newswire4 months ago

    NeuroStar® Advanced Therapy to Host Industry Best Practices Symposia at Clinical TMS Society Annual Meeting

    TMS market leader will share clinical data and expert tools to improve outcomes and maximize treatment success MALVERN, Pa. , Feb. 21, 2019   /PRNewswire/ --  Neuronetics, Inc. (NASDAQ:STIM) —   NeuroStar® ...

  • GlobeNewswire4 months ago

    Neuronetics to Report Fourth Quarter and Fiscal Year 2018 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Feb. 19, 2019 -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that.

  • GlobeNewswire4 months ago

    Neuronetics, Inc. Announces Appointment of Dr. Cheryl R. Blanchard to its Board of Directors

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the appointment of Dr. Cheryl R. Blanchard, President and CEO of Keratin Biosciences, Inc., to its Board of Directors. Dr. Blanchard succeeds Paulina Hill, who has retired from the Board.

  • GlobeNewswire5 months ago

    Neuronetics Announces Preliminary Fourth Quarter and Full Year Revenue

    Neuronetics, Inc. (STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced certain unaudited preliminary fourth quarter and full year 2018 revenue.

  • Who Has Been Buying Neuronetics, Inc. (NASDAQ:STIM) Shares?
    Simply Wall St.6 months ago

    Who Has Been Buying Neuronetics, Inc. (NASDAQ:STIM) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • At FDA, a new goal, then a push for speedy device reviews
    Associated Press7 months ago

    At FDA, a new goal, then a push for speedy device reviews

    WASHINGTON (AP) — Dr. Jeffrey Shuren was adamant: The United States would never cut corners to fast-track the approval of medical devices.